



Unraveling SARS-CoV-2 Pathogenesis: Development of Vaccines and Therapeutics for COVID-19: Version II

Guest Editor:

Dr. Hatem A. Elshabrawy

Department of Molecular and Cellular Biology, College of Osteopathic Medicine, Sam Houston State University, Conroe, TX 77304, USA

Deadline for manuscript submissions:

closed (3 March 2023)

Message from the Guest Editor

Coronaviruses (CoVs) are RNA viruses that have been a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. Currently, the world is concerned about SARS-CoV-2, the causative agent of COVID-19, which was initially identified in the city of Wuhan, China, in December 2019. Tens of thousands of cases and several thousand deaths have been reported in many countries. SARS-CoV-2 is highly contagious based on the number of infected cases to date. There is a need for development of vaccines and effective therapeutics that can control the current outbreak.

We are interested in manuscripts that focus on the replication, viral life cycle, and pathogenesis of SARS-CoV-2. We are also interested in areas of identification of novel drug targets and the development of vaccines and therapeutics for COVID-19. We aim to publish a variety of manuscripts that represent different research studies that investigate unique aspects of viral pathogenesis and life cycle and identify/test different vaccines and antivirals for efficacy against SARS-CoV-2.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com